坏死性凋亡在肝炎以及其他肝病发病中的作用研究进展*

doi:10.3969/j.issn.1672-5069.2016.05.030

摘要/Abstract

摘要： 传统意义上,人们将细胞死亡分为凋亡和坏死两类,而越来越多的研究结果表明坏死性凋亡是一种不同于坏死或凋亡的细胞死亡途径,并在多种疾病发病中发挥着重要作用。坏死性凋亡是调节坏死的一种形式,可以被死亡受体的配体激活,或者在无凋亡状态下被能够诱导死亡受体表达的刺激激活。死亡受体配体对坏死性凋亡激活需要RIP1激酶活性,其进一步介导RIP3和MLKL的激活。RIP3和MLKL是坏死性凋亡下游重要的调节子。RIP1激酶是坏死性凋亡通路中的关键药物靶点,通过坏死抑制素阻断RIP1活性,可以抑制坏死性凋亡的激活,并且在死亡受体配体存在的情况下使得细胞生存和增殖。本文将对坏死性凋亡与凋亡和坏死的区别、坏死性凋亡产生机制及其在肝炎以及其他肝病发病中的作用作一介绍,以期对肝病治疗药物新靶点的发现提供新思路。

关键词: 肝炎, 坏死性凋亡, 坏死, 凋亡

Abstract: Traditionally cell death is divided into two categories,e.g. apoptosis and necrosis. But a growing body of research results show that the necrotic apoptosis is a kind of cell death different from necrosis and apoptosis,and plays an important role in a variety of diseases. Activation of necroptosis by ligands of death receptors requires the kinase activity of RIP1,which mediates the activation of RIP3 and MLKL,two critical downstream mediators of necroptosis. Blocking the kinase activity of RIP1,a key druggable target in the necroptosis pathway,by necrostatins inhibits the activation of necroptosis and allows cell survival and proliferation in the presence of death receptor ligands. In this review,we will discuss the difference between apoptosis,necrosis and necrotizing apoptosis,and we will summarizes the mechanism by which the necrotizing apoptosis occur in liver diseases.

Key words: Hepatitis, Necroptosis, Necrosis, Apoptosis

宋金玥, 任锋综述, 张桓虎审校. 坏死性凋亡在肝炎以及其他肝病发病中的作用研究进展^*[J]. 实用肝脏病杂志, 2016, 19(5): 616-619.

Song Jinyue, Ren Feng, Zhang Huanhu.. Necroptosis and its role in hepatitis and other liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(5): 616-619.

参考文献

[1] Ziegler U,Groscurth P. Morphological features of cell death. News Physiol Sci,2004,19（3）:124-128.
[2] Taylor RC,Cullen SP,Martin SJ. Apoptosis:controlled demolition at the cellular level. Nat Rev Mol Cell Biol,2008,9（3）:231-241.
[3] Proskuryakov SY,Konoplyannikov AG,Gabai VL. Necrosis:a specific form of programmed cell death. Exp Cell Res,2003,283（1）:1-16.
[4] Vanlangenakker N,VandenBerghe T,Krysko DV,et al. Molecular mechanisms and pathophysiologyof necrotic cell death. Curr Mol Med,2008,8（3）:207-220.
[5] Chan FK,Shisler J,Bixby JG,et al. A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses. J Chem Biol Phys Sci,2003,278（51）:51613-51621.
[6] Cho YS,Challa S,Moquin D,et al. Phosphorylation-driven assembly of the RIP1-RIP3complex regulates programmed necrosis and virus-inducedinflammation.Cell,2009,137（6）: 1112-1123.
[7] Fulda S. The mechanism of necroptosis in normal and cancer cells. Cancer Biol Ther,2013,14（11）: 999-1004.
[8] Wu W,Liu P,Li J. Necroptosis:an emerging form of programmed cell death. Crit Rev Oncol Hematol,2012,82（3）: 249-258.
[9] Holler N,Zaru R,Micheau O,et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol,2000,1（6）:489-495.
[10] Wu W,Liu P,Li J. Necroptosis:an emerging form of programmed cell death. Crit Rev Oncol Hematol,2012,82（3）: 249-258.
[11] Festjens N,Vanden Berghe T,Cornelis S,et al. RIP1,a kinase on the crossroads of a cell’s decision to live or die. Cell Death Differ,2007,14（3）:400-410.
[12] Degterev A,Huang Z,Boyce M,et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol,2005,1（2）:112-119.
[13] Moriwaki K,Chan FK. RIP3:a molecular switch for necrosis and inflammation. Genes Dev,2013,27（15）:1640-1649.
[14] An J,Mehrhof F,Harms C,et al. ARC is a novel therapeutic approach against acetaminophen-induced hepatocellular necrosis. J Hepatol,2013,58（2）:297-305.
[15] Roychowdhury S,McMullen MR,Pisano SG,et al. Absence of receptor interacting protein kinase 3 preventsethanol-induced liver injury. Hepatology,2013,57（5）:1773-1783.
[16] Ramachandran A,McGill MR,Xie Y,et al. Receptor interacting protein kinase 3 is a criticalearly mediator of acetaminophen-
induced hepatocyte necrosis in mice. Hepatology,2013,58（6）:2099-2108.
[17] Moriwaki K,Chan FK. RIP3:a molecular switch for necrosis and inflammation. Genes Dev,2013,27（15）:1640-1649.
[18] Zhang DW,Shao J,Lin J,et al. RIP3,an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science,2009,325（5938）:332-336.
[19] Mannon RB. Necroptosis in solid organ transplantation:a missing link to immune activation. Am J Transplant,2013,13（11）:2785-2786.
[20] Lau A,Wang S,Jiang J,et al. RIPK3-mediated necroptosis promotes donor kidney inflammatory injury and reduces allograft survival. Am J Transplant,2013,13（11）:2805-2818.
[21] Christofferson DE,Li Y,Hitomi J,et al. A novel role for RIP1 kinase in mediating TNFalpha production. Cell Death Dis,2012,3（6）:e320-410.
[22] Berger SB,Kasparcova V,Hoffman S,et al. Cutting edge:RIP1 kinase activity is dispensable for normal development but is a key regulator of inflammation in SHARPIN-deficient mice. J Immunol,2014,192（12）:5476-5480.
[23] Cuda CM,Misharin AV,Gierut AK,et al. Caspase-8 acts as a molecular rheostat to limit RIPK1-and MyD88-mediated dendritic cell activation. J Immunol,2014,192（12）:5548-5560.
[24] Vince JE,Wong WWL,Gentle I,et al. Inhibitor of apoptosis proteins limit RIP3 kinase-dependent interleukin-1 activation.Immunity,2012,36（2）:215-227.
[25] Jouan-Lanhouet S,Arshad MI,Piquet-Pellorce C,et al. TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation. Cell Death Differ,2012,19（12）: 2003-2014.
[26] Liedtke C,Bangen JM,Freimuth J,et al. Loss of caspase-8 protects mice against inflammation-related hepatocarcinogenesis but induces non-apoptotic liver injury. Gastroenterology,2011,141（6）:2176-2187.
[27] Sharma M,Gadang V,Jaeschke A. Critical role for mixed lineage kinase 3 in acetaminophen-induced hepatotoxicity. Mol Pharmacol,2012,82（5）:1001-1007.
[28] Li JX,Feng JM,Wang Y,et al. The B-Raf（V600E） inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury. Cell Death Dis,2014,5（6）:e1278.
[29] Roychowdhury S,Chiang DJ,Mandal P,et al. Inhibition of apoptosis protects mice from ethanol-mediated acceleration of early markers of CCl4 -induced fibrosis but not steatosis or inflammation. Alcohol Clin Exp Res,2012,36（7）:1139-1147.
[30] Roychowdhury S,McMullen MR,Pisano SG,et al. Absence of receptor interacting protein kinase 3 prevents ethanol-induced liver injury. Hepatology,2013,57（5）:1773-1783.
[31] TakahashiN,Duprez L,Grootjans S,et al. Necrostatin-1 analogues:critical issues on the specificity,activity and in vivo use in experimental disease models. Cell Death Dis,2012,3（11）:e437.
[32] Vandenabeele P,Grootjans S,Callewaert N,et al. Necrostatin-1 blocks both RIPK1 and IDO: consequences for the study of cell death in experimental disease models. Cell Death Differ,2013,20（2）:185-187.
[33] Nagata K,Suzuki H,Sakaguchi S. Common pathogenic mechanism in development progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis. J Toxicol Sci,2007,32（5）:453-468.
[34] Csak T,Dolganiuc A,Kodys K,et al. Mitochondrial antiviral signaling protein defect links impaired antiviral response and liver injury in steatohepatitis in mice. Hepatology,2011,53（6）: 1917-1931.
[35] Gautheron J,Vucur M,Reisinger F,et al. A positive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis. EMBO Mol Med,2014,6（8）:1062-1074.
[36] Hotchkiss RS,Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med,2003,348（2）:138-150.
[37] Bantel H,Schulze-Osthoff K. Cell death in sepsis: a matter of how,when,and where. Crit Care,2009,13（4）:173.
[38] Duprez L,Takahashi N,Van Hauwermeiren F,et al. RIP kinase-dependent necrosis drives lethal systemic inflammatory response syndrome. Immunity,2011,35（6）:908-918.
[39] Polykratis A,Hermance N,Zelic M,et al. Cutting edge: RIPK1 kinase inactive mice are viable and protected from TNF-induced necroptosis in vivo. J Immunol,2014,193（4）:1539-1543.
[40] Newton K,Dugger DL,Wickliffe KE,et al. Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis. Science,2014,343（6177）:1357-1360.
[41] Linkermann A,Brasen JH,De Zen F, et al. Dichotomy between RIP1-and RIP3-mediated necroptosis in tumor necrosis factor-alpha-induced shock. Mol Med,2012,9（18）:577-586.
[42] Wu J,Huang Z,Ren J,et al. Mlkl knockout mice demonstrate the indispensable role of Mlkl in necroptosis. Cell Res,2013,23（8）:994-1006.
[43] 陈柏年,杜冠华. 坏死性凋亡：一种新的细胞死亡方式.生理学进展,2010,41（02）：95-102.

坏死性凋亡在肝炎以及其他肝病发病中的作用研究进展^*

Necroptosis and its role in hepatitis and other liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	徐飞, 李伟荣. 黄芪甲苷对CCL₄所致肝损伤大鼠的保护作用^*[J]. 实用肝脏病杂志, 2019, 22(6): 808-811.
[2]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[3]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[4]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[5]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[6]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[7]	马丽英, 沈利娟. 妊娠后期应用替诺福韦治疗血清HBV高载量孕妇阻断HBV母婴传播的疗效及安全性分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 836-839.
[8]	潘美民, 李文娟, 蒋芳清, 杨丽晖, 谭永卫, 何娟, 阮建文, 蔡春琳. 慢性丙型肝炎患者血清IL-17A、FGF和IL-7水平与丙型肝炎病毒感染自发清除临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 840-843.
[9]	汪道伟, 方坚, 范凌. 自身免疫性肝炎患者血清IL-21和趋化因子水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 844-847.
[10]	杨才勇, 陈娜, 李奎, 江自成, 卜蓉蓉. 慢性丙型肝炎和丙型肝炎肝硬化患者外周血Treg和Th17水平变化临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 868-871.
[11]	曾艳妮, 张灿, 毕俊英, 刘良进, 孟俊, 秦涛. MRI长时间延迟增强扫描诊断肝脏孤立性坏死性结节价值研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 900-903.
[12]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[13]	杜科业, 杨东亮, 刘嘉. 慢性乙型肝炎与调节性T细胞研究进展^*[J]. 实用肝脏病杂志, 2019, 22(5): 613-616.
[14]	廖桂婵, 彭颉, 张小勇. 肝细胞介导的天然免疫应答参与控制乙型肝炎病毒感染^*[J]. 实用肝脏病杂志, 2019, 22(5): 617-619.
[15]	蔡美洪, 王绮夏, 马雄. 肝内胆管缺失的病理生理学研究进展^*[J]. 实用肝脏病杂志, 2019, 22(5): 620-623.